Our Bold Vision: ARMI’s Strategic Plan 2020-2025

ARMI is delighted to unveil our 2020-2025 Strategic Plan; designed to realise ARMI’s vision of improved quality of life by unlocking the body’s innate regenerative potential.

The five-year plan is a roadmap to support the Institute’s mission to discover new regenerative therapies through conducting cutting edge research and forming collaborative networks with the best scientists and clinicians worldwide to develop novel therapies.

The five-year plan is a roadmap to support the Institute’s mission to discover new regenerative therapies through conducting cutting edge research and forming collaborative networks with the best scientists and clinicians worldwide to develop novel therapies.

The plan has six strategic focus areas: 1) Building strength at scale; 2) Research excellence; 3) Clinical connections, translation and commercialisation; 4) Investment, engagement and funding; 5) External engagement and 6) Future perspectives with activities to progress each in a carefully considered phased process.

ARMI is already well-placed to deliver the plan. Commencing with the previous Director,  Professor Nadia Rosenthal, and continuing with current Director Professor Peter Currie, ARMI has always had strong leadership and focus. With the continued support of Monash University, the Institute will continue to grow; recruiting talented group leaders from around the world and attracting bright young minds to our education program while supporting their journey through the ups-and-downs of research.

In addition to maintaining an exceptional research program, ARMI has renewed its commitment to industry, developing several programs to accelerate engagement. These include the development of the Centre for Commercialization of Regenerative Medicine (CCRM) Australia, the establishment of an Industry Advisory sub-Committee, an Industry Mentoring Program for students and postgraduate staff, industry placements through the Master of Biotechnology program and a deep relationship with Industry Mentoring Network in STEM (IMNIS) and CCRM Australia. 

Another significant focus for ARMI in the next five years is establishing new and deepening existing clinical connections with clinicians and health service providers, both within Australia and abroad. Notably, ARMI looks forward to the completion of the Monash Heart Hospital.

Communicating our efforts to a broader audience, both within the science community and the general public, is key to helping everyone understand the opportunities and risks of regenerative medicine research and the treatments that may result from our work. Biomedical research is a public good, and for the most part, publicly-funded, so external engagement is not merely an obligation, but our duty. Through this, ARMI can advocate for our work and maintain our “social licence to operate.”

All in all, high-quality research output, increased industry engagement and clinical links will continue to enhance the financial viability and overall sustainability of ARMI.

All in all, high-quality research output, increased industry engagement and clinical links will continue to enhance the financial viability and overall sustainability of ARMI.

The different and deeply interlinked strategic focus areas are creating a cycle that ultimately enables ARMI scientists to continue their cutting edge work, develop novel treatments and medical devices and improve the lives of patients.

With the ARMI Strategic Plan for 2020 – 2025, we now have a roadmap.

Read the Strategic Plan here.